

دراسة تأثير العمليات الجراحية للسمنة على كلا من تركيز
مشابه ببتيد الجلوكاجون-١ بالمصل و مقاومة الانسولين بين
مرضي السمنة المصاحبة لداء السكري من النوع الثاني

رسالة

توطئة للحصول على درجة الدكتوراه

فى أمراض الباطنة العامة

مقدمة من

الطبيبة/ نسمة علي ابراهيم علي

بكالوريوس الطب و الجراحة - ماجستير أمراض الباطنة العامة

تحت اشراف

أ.د/ صلاح الدين أحمد أبو شلبايه

أستاذ أمراض الباطنة العامة والغدد الصماء

كلية الطب - جامعة عين شمس

أ.د/ علاء عباس صبري مصطفى

أستاذ الجراحة العامة

كلية الطب - جامعة عين شمس

أ.د/ سلوي صديق حسني

أستاذ أمراض الباطنة العامة

كلية الطب - جامعة عين شمس

د/ منال محمد أبو شادي

أستاذ مساعد أمراض الباطنة العامة

كلية الطب - جامعة عين شمس

د/ ميرام محمد محمود بخيت

مدرس أمراض الباطنة العامة

كلية الطب - جامعة عين شمس

كلية الطب

جامعة عين شمس

٢٠١٣

**Study of The Effect of Bariatric Surgery on Serum
Glucagon Like Peptide-1 Concentration and Insulin
Resistance among Obese Type 2 Diabetic Patients**

Thesis

*Submitted for Partial Fulfillment of M.D Degree
In Internal Medicine*

By

Nesma Ali Ibrahim

M.B, B.Ch.,- M.Sc,

Under Supervision Of

Prof. Dr./Salah EL Din Ahmed Abu
Shelbaya

***Professor of Internal Medicine and Endocrinology
Faculty of Medicine – Ain Shams University***

Prof. Dr./ Alaa Abbas Sabry Mostafa

***Professor of General Surgery
Faculty of Medicine – Ain Shams University***

Prof. Dr./Salwa Seddik Hosny

***Professor of Internal Medicine
Faculty of Medicine – Ain Shams University***

Dr./ Manal Mohamed Abu Shady

***Assistant professor of Internal Medicine
Faculty of Medicine – Ain Shams University***

Dr./ Meram Mohamed Mahmoud Bekhet

***Lecturer of Internal Medicine
Faculty of Medicine – Ain Shams University***

**Faculty of Medicine
Ain Shams University**

2013

List of contents

	Page
Acknowledgement	I
List of Abbreviations	II
List of Tables	V
List of Figures.....	VI
 Introduction	 1
Aim of the work.....	5
 Review of Literature	
I - Bariatric surgery	6
II- Glucagon Like Peptide-1.....	47
III- Insulin Resistance	71
 Subjects and Methods	 89
Results	107
Discussion	129
Summary and Conclusion	148
Recommendations and perspectives	152
References	154
Arabic summary	

Acknowledgement

*No words can express my deepest appreciation and profound respect to **Professor Dr. Salah Shelbaya**, Professor of Internal Medicine and Endocrinology, Ain Shams University, for his continuous guidance, support and constructive criticism through the work. He has generously devoted much of his time and his effort for planning and supervision of this study.*

*My profound gratitude to **Professor Dr. Alaa Abbas**, Professor of General Surgery, Ain Shams University, for his kind supervision and support. It was great honor to work under his supervision.*

*My profound gratitude to **Professor Dr. Salwa Seddik**, Professor of Internal Medicine and Endocrinology, Ain Shams University, for her kind supervision and support. It was great honor to work under her supervision.*

*Also, my profound gratitude to **Dr. Manal Abu Shady**, assistant professor of Internal Medicine and Endocrinology, Ain Shams University, for her kind supervision and support.*

*Also, my profound gratitude to **Dr. Meram Bekhet**, lecturer of Internal Medicine and Endocrinology, Ain Shams University, for her great care and support.*

Nesma Ali Ibrahim

List of Abbreviations

11β-HSD1	: 11 β -hydroxysteroid dehydrogenase type 1
AMP	: Adenosine monophosphate
AMPK	: AMP-activated protein kinase
ASBS	: American Society for Bariatric Surgery
ASMBS	: American Society for Metabolic and Bariatric Surgery
ATMs	: Adipose tissue macrophages
ATP	: Adenosine triphosphate
BMI	: Body mass index
BPD	: Bilio–pancreatic diversion
CCK	: Cholecystokinin
CNS	: Central nervous system
COE	: Center of Excellence
CPT-1	: Carnitine palmitoyltransferase-1
CRP	: C-reactive protein
DJB	: Duodenal–jejunal bypass
DPP-4	: Dipeptidyl peptidase-4
ELISA	: Enzyme-Linked Immunosorbent Assay
ER	: Endoplasmic reticulum
ERK	: Extracellular signal-regulated kinase
FA	: Fatty acids
GIP	: Glucose- dependent insulinotropic peptide
GK	: Goto-Kakizaki
GLP-1	: Glucagon-like peptide-1
GLP-1R	: GLP-1 receptors
GLP-2	: Glucagon-like peptide-2
GLUT-4	: Glucose transporter-4
GPR	: G-proteincoupled receptor
GRPP	: Glicentin-related pancreatic polypeptide
GSK3	: Glycogen synthase kinase- 3
HDL-Chol	: High-density lipoprotein cholesterol
HGP	: Hepatic glucose production
HOMA-IR	: Homeostasis model assessment of insulin resistance
ICV	: Intracerebral ventricular

List of Abbreviations (Cont.)

IGT	: Impaired glucose tolerance
IKKβ	: Inhibitor of nuclear factor- κ B (NF- κ B) kinase- β
IL-6	: Interleukin-6
IR	: Insulin resistance
IRS	: Insulin receptor substrate
JNK	: JUN N-terminal kinase
LABS	: Longitudinal Assessment of Bariatric Surgery
LADA	: Latent autoimmune diabetes of adulthood
LAGB	: Laparoscopic adjustable gastric banding
LDL-Chol	: Low-density lipoprotein cholesterol
LEAD	: Liraglutide effect and action in diabetes
MAPK	: Mitogen-activated protein kinase
MEK	: ERK kinase
MetS	: Metabolic syndrome
MPGF	: Major proglucagon fragment
NEFA	: Non esterified fatty acids
NF-κB	: Nuclear factor- κ B
NGT	: Normal glucose tolerance
NIH	: National Institutes of Health
PAI-1	: Plasminogen activator inhibitor-1
PAM	: Peptide amidating monooxygenase
PC	: Prohormone convertase
PDK1	: Phosphoinositide-dependent protein kinase- 1
PG	: Plasma glucose
PGC-1	: PPAR γ coactivator 1
PI3K	: Phosphatidylinositol 3-kinase
PKA	: Protein kinase A
PKB	: Protein kinase B
PKC	: Protein Kinase C
PPARγ	: Peroxisome proliferator-activated receptor γ
PrG	: Proglucagon
PTB1B	: Protein Tyr phosphatase-1B
PTH	: Parathyroid hormone
PYY	: Peptide YY
RBP4	: Retinol-binding protein 4

List of Abbreviations (Cont.)

ROS	: Reactive oxygen species
RP	: Restrictive procedures
RYGB	: Roux-en-Y gastric bypass
SA-HRP	: Streptavidin-horseradish peroxidase
SG	: Sleeve gastrectomy
SOCS	: Suppressor of cytokine signalling
SOS	: Swedish Obesity Study
SRC	: Surgical Review Corporation
T2DM	: Type 2 diabetes mellitus
TLR4	: Toll-Like Receptor 4
TNFα	: Tumor necrosis factor α
VBG	: Vertical banded gastroplasty
WHO	: World Health Organization
WHR	: Waist to hip ratio

List of Tables

	Page
Table 1: World Health Organization Classifications for Overweight/Obesity	7
Table 2: Reports in the literature on the early effects of roux-en-Y gastric bypass (RYGB) and biliopancreatic diversion (BPD) on type 2 diabetes control and impaired glucose tolerance (IGT).....	26
Table 3: Common Bariatric Procedures: Risks and Benefits	37
Table 4: Clinical Impact of Select Bariatric Surgeries	38
Table 5: Possible Nutritional Deficiencies/Outcomes Due to Bariatric Surgery.....	45
Table 6: Abnormalities associated with insulin resistance/compensatory hyperinsulinemia.....	72
Table 7: Reference values of cholesterol	102
Table 8: Reference values of HDL	104
Table 9: Comparison among the three studied groups regarding the baseline results of different variables.....	110
Table 10: Comparison among the three studied groups regarding the baseline results of laboratory investigations.....	111
Table 11: Correlation between fasting GLP-1 level and the different variables	114
Table 12: Correlation between 2 hours postprandial GLP-1 level and the different variables.....	117
Table 13: Comparison between the preoperative and postoperative results of Group I	119
Table 14: Comparison among the three studied groups 3 months after RYGB regarding the different variables	123
Table 15: Comparison between the preoperative and postoperative usage of antidiabetic medications among patients of Group I.....	125
Table 16: Comparison between the preoperative and postoperative usage of the different antidiabetic medications.....	127
Table 17: Comparison between the preoperative and 3 months postoperative usage of the antihypertensive and hypolipidemic medications	128

List of Figures

	Page
Figure 1: Intestinal factors that contribute to the pathophysiology of T2DM	12
Figure 2: The anti-incretin hypothesis to explain the alterations of glucose metabolism in type 2 diabetes	13
Figure 3: Conventional bariatric operations	15
Figure 4: Other methods of metabolic surgery	16
Figure 5: RYGB and a gastric-sparing variant of RYGB known as the DJB.....	33
Figure 6: The "ominous octect." Pathologic defects in patients with type 2 diabetes mellitus	48
Figure 7: Proglucagon is a protein precursor of glucagon and GLPs	50
Figure 8: The L-cell with components that may be involved in triggering or modulating GLP-1 secretion	53
Figure 9: Endocrine, inflammatory, and neuronal pathways link obesity to insulin resistance.....	74
Figure 10: Obesity-associated intrinsic mediators of insulin resistance	84
Figure 11: Comparison between the studied groups regarding fasting GLP-1 level.....	113
Figure 12: Comparison between the studied groups regarding 2 hours postprandial GLP-1 level.....	113
Figure 13: Correlation between fasting GLP-1 level and BMI	115
Figure 14: Correlation between fasting GLP-1 level and fasting plasma glucose.....	115
Figure 15: Correlation between fasting GLP-1 level and HOMA IR.....	116
Figure 16: Correlation between fasting GLP-1 level and HDL-C.....	116
Figure 17: Correlation between 2 hours postprandial GLP-1 level and BMI. 118	
Figure 18: Correlation between 2 hours postprandial GLP-1 level and HbA1c	118
Figure 19: Comparison between the pre-operative & post-operative results regarding fasting and 2 hours postprandial GLP-1 levels	120

List of Figures (Cont.)

	Page
Figure 20: Comparison between the pre-operative & post-operative results regarding fasting and 2 hours postprandial plasma glucose.....	120
Figure 21: Comparison between the pre-operative & post-operative results regarding BMI.....	121
Figure 22: Comparison between the pre-operative & post-operative results regarding HOMA IR.....	121
Figure 23: Comparison between the pre-operative & post-operative results regarding the lipid profile	122
Figure 24: Descriptive figure for the percentage of the postoperative usage of the antidiabetic medications among patients of GroupI.....	126
Figure 25: Comparison between the preoperative and postoperative usage of antidiabetic medications among patients of GroupI.....	126
Figure 26: Comparison between the preoperative and the postoperative usage of the different antidiabetic medications.....	127
Figure 27: Comparison between the preoperative and the postoperative usage of the antihypertensive and hypolipidemic medications	128

INTRODUCTION

Type 2 diabetes mellitus is a complex metabolic disease characterized by insulin resistance and progressive failure of pancreatic beta cells, resulting in hyperglycemia (*Kashyap and DeFronzo, 2007*). The increasing prevalence of obesity worldwide is accompanied by an explosion in the prevalence of type 2 diabetes; about 60% of all cases of diabetes are attributable to obesity (*Yach et al., 2006*).

Obesity, a potent risk factor for type 2 diabetes, contributes to its development by inducing insulin resistance and inflammation, which in turn impair glucose regulation (*Mokdad et al., 2003*). Fat deposits in the abdomen, muscles, and liver contribute to elevations of circulating free fatty acids and adipocyte-derived cytokines that mediate insulin resistance and inflammatory pathways (*Itani et al., 2002*).

Existing medical therapeutic strategies to achieve and maintain clinically significant weight loss remain limited. Surgical procedures for the treatment of obesity are, however, highly effective in achieving substantial and sustained weight loss, but they are technically demanding, costly and carry small but significant rates of morbidity and mortality (*Carel et al., 2006*).

Glycemic control in diabetic patients improves markedly within days of bariatric surgery, which suggests that the procedures alter the hormones that control insulin secretion (**Rubino, 2006**). The enteroinsular axis includes the gut hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent insulintropic peptide (GIP). These hormones, also known as *incretins*, are secreted by intestinal L and K cells, respectively, in response to nutrients and directly enhance insulin secretion (**Fetner et al., 2005**).

Bariatric procedures were classified as restrictive, malabsorptive, or combined, reflecting the purported mechanism of weight loss (**Rubino, 2006**).

Restrictive procedures, such as laparoscopic adjustable gastric banding (LAGB) and vertical banded gastroplasty (VBG), greatly reduce the volume of the stomach to decrease food intake and induce early satiety. Malabsorptive procedures, such as biliopancreatic diversion (BPD), shorten the small intestine to decrease nutrient absorption. Combined procedures, such as the Roux-en-Y gastric bypass (RYGB), incorporate both restrictive and malabsorptive elements (**Murphy and Bloom, 2006**).

Both BPD and RYGB alter the secretion of orexigenic and anorexigenic gut peptides, which interact with appetitive centers in the arcuate nucleus of the hypothalamus to decrease

appetite. On average, bariatric surgery reduces body mass index by 10 to 15 kg/m² and weight by 30 to 50 kg (**Bult *et al.*, 2008**).

Dramatic improvements in glycemic control have been observed in subjects with T2DM following bariatric surgery, and specifically the Roux-en-Y gastric bypass (RYGB) procedure (**Schauer *et al.*, 2003**). In the early postoperative period following RYGB, many patients with T2DM discontinue all antidiabetic medication, and may achieve normal fasting plasma glucose concentrations even before substantial weight loss has occurred (**Clements *et al.*, 2004**).

Bariatric surgery alters both insulin secretion and insulin sensitivity, thus improving glucose regulation (**Kashyap *et al.*, 2010**). It has been postulated that the improvements in glycemic control, reduction in appetite, and subsequent weight loss following bypass surgery may be due to changes in circulating gut hormones (**Rubino and Marescaux, 2004**).

Glucagon-like peptide-1 is a potent insulin secretagogue that is secreted by the L cells of the distal ileum in response to ingested nutrients and is inactivated by the enzyme dipeptidyl peptidase IV (DPP-IV) (**Holst, 2007**).

By activating adenylate cyclase, GLP-1 acts on pancreatic islets to augment glucose-dependent insulin secretion. The subsequent increase in insulin levels within

islets inhibits glucagons secretion, possibly through direct activation of GLP-1 receptors on α cells (*Flint et al., 2001*). Glucagon-like peptide-1 also slows gastric emptying, which delays digestion and blunts postprandial glycemia, and acts on the central nervous system to induce satiety and decrease food intake. Finally, GLP-1 increases glycogenesis in hepatocytes and skeletal muscle and increases lipogenesis in adipocytes, which may improve insulin sensitivity (*Luque et al., 2002*).

AIM OF THE WORK

The aim of this study is to assess the effect of bariatric surgery on serum glucagon like peptide-1 (GLP-1) concentration and insulin resistance among obese type 2 diabetic patients.